Ascentage Pharma Sets Out Board Line-Up and Key Committee Roles
I'm PortAI, I can summarize articles.
Ascentage Pharma Group International has announced its board composition, led by Executive Director and Chairman Dr. Yang Dajun, featuring a mix of directors with expertise in science and industry. The company detailed its governance committees—Audit, Remuneration, Nomination, and R&D—emphasizing oversight and decision-making. The latest analyst rating for its stock (HK:6855) is a Hold with a price target of HK$63.00. Ascentage focuses on innovative drug R&D and is listed on the Hong Kong Stock Exchange under stock code 6855, with a market cap of HK$19.85B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments